Activities

Clinuvel is focused on commercializing our leading drug candidate afamelanotide (CUV1647).

Afamelanotide is a photoprotective against damage to the skin by UV and sunlight.

Clinuvel is transitioning from a pharmaceutical research and development company to a company with commercial product sales given market size assumptions.